DHGWA
NTLA icon

Dixon Hughes Goodman Wealth Advisors’s Intellia Therapeutics NTLA Stock Holding History

Dixon Hughes Goodman Wealth Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$36K Hold
500
– – 0.01% 355
2021
Q4 		$59K Buy
+500
New +$62.6K 0.02% 244

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Dixon Hughes Goodman Wealth Advisors's NTLA Position: Q1 2022 in Review

Dixon Hughes Goodman Wealth Advisors held its Intellia Therapeutics (NTLA) position steady in Q1 2022 at 500 shares worth $36K. The position accounts for 0.01% of the portfolio, ranked #355.

Dixon Hughes Goodman Wealth Advisors first reported a position in NTLA in Q4 2021 and has held it in 2 quarters since. The position peaked at $59K in Q4 2021. 348 funds tracked by Wall St. Rank hold NTLA as of Q1 2022.

  • Dixon Hughes Goodman Wealth Advisors held 500 shares of Intellia Therapeutics worth $36K as of Q1 2022.
  • Dixon Hughes Goodman Wealth Advisors left its Intellia Therapeutics share count unchanged in Q1 2022.
  • Intellia Therapeutics made up 0.01% of Dixon Hughes Goodman Wealth Advisors's portfolio in Q1 2022, its #355 holding.
  • Dixon Hughes Goodman Wealth Advisors first reported a position in Intellia Therapeutics in Q4 2021 and has held it in 2 quarters since.
  • Dixon Hughes Goodman Wealth Advisors's Intellia Therapeutics position peaked at $59K in Q4 2021.
  • 348 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2022.

Based on Dixon Hughes Goodman Wealth Advisors's 13F filing for Q1 2022, filed 4 Apr 2022.